4C Acquires Stake in iQ Media, Jointly Create Kinetiq, World’s Largest Unified TV Intelligence Network
4C and iQ Media today announce the investment in and creation of a new entity, Kinetiq (www.kinetiq.tv), that combines iQ Media and 4C’s Teletrax. Kinetiq will serve as the world’s largest unified TV intelligence network, offering paid and earned media measurement, monitoring and signaling across local, national and global markets.
Kinetiq will operate globally, with U.S. headquarters in Philadelphia, Pennsylvania and European headquarters in Eindhoven, Netherlands. Kevin Kohn, CEO of iQ Media, will serve as CEO of Kinetiq with key management from 4C and iQ Media completing the leadership team. Existing investors from 4C and iQ Media, including Jump Capital, Edison Partners, GMH Ventures, Kayne Capital and Civolution Holdings will remain involved. The board of directors for the new entity is comprised of Kevin Kohn of Kinetiq, Dr. Alok Choudhary of 4C, Kelly Ford of Edison Partners, Sach Chitnis of Jump Capital, and one independent member to be appointed.
Kinetiq’s combined global TV intelligence network will enable broadcasters, brands, agencies and software partners to evaluate and measure TV and video with the same speed, accuracy and agility as digital. Kinetiq combines iQ Media’s ability to identify paid and earned brand mentions, nationally and across all 210 U.S. DMAs, with the global Teletrax network: 85+ countries, across more than 250 global capture locations and approaching 2,500 TV stations.
“Historically, TV attribution has been limited to paid advertising, overlooking the impact and return on brand exposure within the content—where audiences are most engaged,” said Kevin Kohn, CEO of Kinetiq. “As advertisers and agencies evolve their paid TV strategies to include earned media and brand sponsorship, Kinetiq is uniquely positioned to help quantify the true return on these investments. We are thrilled to join forces with the talented team operating Teletrax to make this a reality.”
“Bringing together iQ Media and Teletrax creates powerful new solutions for the industry and efficiencies of scale for the company,” said Lance Neuhauser, CEO of 4C. “We’re excited to leverage the unmatched strength of Kinetiq’s global TV intelligence network to fuel the media analytics available to brands through the Scope by 4C™ platform.”
Together, iQ Media and Teletrax bring Kinetiq’s clients the most comprehensive understanding of TV performance currently on the market, including:
TV & Media Monitoring—Real Time or Retroactive: The ability to track and evaluate the entirety of earned media coverage, with unparalleled access to real-time and historical broadcast TV and media content—including more than 40 million hours of TV programming.
Content Identification & Tracking: Kinetiq employs fingerprinting and watermarking capabilities to offer global insight into where, when, and for how long your content was broadcast.
Ad Catalogue as a Service: Kinetiq’s growing ad catalog boasts more than 500,000 indexed ads from over 32,000 brands. The company plans to make the catalogue widely available, via subscription, for competitive analysis and creative auditing. The catalogue spans all 210 U.S. DMAs and national ads across the 85 markets Kinetiq serves.
Sponsorship Measurement: A unified understanding of how brand sponsorships, in the form of events, athletes, product placements and properties, are performing in- and out-of-event across live TV.
TV Attribution and Advanced Audience Segments: Through a network of connected smart TVs, Kinetiq can link TV brand exposures to household-level data and brands’ first party data—measuring ROI across paid, earned and sponsorship.
Second Screen Signaling: Kinetiq can activate ads on mobile devices and computers any time a brand is seen or heard on TV through signals sent to media buying platforms, including search, social media, mobile, and digital.
Kinetiq’s roster of clients includes Mercedes-Benz, Fox Broadcasting Company, Google, Mitsubishi, Newell Brands, US Bank, AP, and Reuters. Progress Partners represented iQ Media in the transaction.
Kinetiq is taking a bold new approach to TV data and analytics. Through the union of iQ Media and 4C’s Teletrax, Kinetiq’s intelligent monitoring, measurement and signaling solutions offer the most comprehensive view of TV performance across global, national and local markets. Kinetiq delivers valuable insights on audiences and engagement across all paid, earned and sponsorship investments. Brands, agencies, broadcasters and ISVs like Mercedes-Benz, Fox Broadcasting Company, and Google use Kinetiq to better understand their true ROI on TV, locally and globally. Headquarters are located in Philadelphia and Eindhoven, Netherlands. Visit www.kinetiq.tv for more information.
4C is a global data science and marketing technology company that delivers self-service software for brands to execute video-centric marketing and optimize business outcomes. Leading brands, global agencies, and media owners trust the Scope by 4C™ platform to identify their most valuable consumers and reach them across channels and devices. With nearly $2 billion in annualized advertising spend running through Scope, 4C enables unified audiences, activation, and analytics on linear television, social media, over-the-top content, and digital commerce. Founded in 2011 and based in Chicago, 4C has staff in 16 worldwide locations throughout the United States, United Kingdom, the Netherlands, France, Hong Kong, India, Singapore, and the Philippines. Visit www.4Cinsights.com for more information.
Channel V Media
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail email@example.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu